1,4-diphenyl-1H-imidazole and 2,4-diphenylthiazole derivatives and preparation method therefor and use thereof
Provided are 1,4-diphenyl-1H-imidazole and 2,4-diphenylthiazole derivatives having a structure represented by Formula I, a preparation method therefor and uses thereof: wherein R 1 is any one of H, OH, and OCH 3 , R 2 is any one of H, NO 2 , CH 3 , CF 3 , SO 2 CH 3 , COOCH 3 , or CONHCH 3 , R 3 is any one of H, NO 2 , OCH 3 , or CF 3 , R 4 is selected from H, CF 3 , or Cl, R 5 is any one of H, Cl, CF 3 , or NHCH 3 , and R 6 is any one of OCF 3 , CF 3 , or CN; V is either C or N, W is either CH or N, X is a C atom, Y is either CH or N, and Z is either CH or S. This compound can be used in preparation of anti-inflammatory adjuvants, TLR1 or TLR2 agonists, and anti-tumor agents and for regulating the activity activation level of TLR1 and TLR2 alkaline phosphatases in vitro and in vivo.
1. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound has a structural formula below: Compound 23
2. A preparation method of the compound according to claim 1 , comprising the following steps:
1) allowing compound A1
to react as catalyzed by inethyllithium to obtain compound A2
allowing the compound A2
to react in a presence of tetrabutylammonium tribromide to obtain compound A3
2) allowing compound B1
to react in methylamine to give an amino-substituted compound B2
reducing the amino-substituted compound B2 to obtain compound B3
or aminomethylating compound B5
to obtain the compound B 3 ;
3) reacting compound B3 with triethyl orthofomiate to form a ring to obtain compound B4
4) reacting the compound 134 with the compound A3 to obtain compound B6
5) refluxing the compound B 6 under acidic conditions to obtain the compound according to claim 1 ;
wherein R 1 , R 2 and R 6 in the compounds A3, B1, B2, B3, B4 and B5 for preparing the compound according to claim 1 are as follows:
R 1 ═OH, R 6 ═CF 3 , R 2 ═SO 2 CH 3 .
3. A pharmaceutical composition, comprising the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or an excipient.
4. A method for regulating an activity activation level of URI and TLR2 alkaline phosphatases in vivo, comprising administering the compound according to claim 1 to a subject.